Terms: = Gastric cancer AND PREX2, 6230420N16Rik, DEPDC2, 80243, ENSG00000046889, FLJ12987, DEP_2, P-REX2
9 results:
1. Comprehensive Multiomics Analyses Establish the Optimal Prognostic Model for Resectable gastric cancer : Prognosis Prediction for Resectable GC.
Guo S; Wang E; Wang B; Xue Y; Kuang Y; Liu H
Ann Surg Oncol; 2024 Mar; 31(3):2078-2089. PubMed ID: 37996637
[TBL] [Abstract] [Full Text] [Related]
2. Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer.
Chen X; Bai K; Zhang Y; Xu Y; Huo Y; Wang S; Zou Y; Qi X; Guo R; Ou Q; Liu D; Yin S; Chen S; Bu H
J Transl Med; 2023 May; 21(1):296. PubMed ID: 37131253
[TBL] [Abstract] [Full Text] [Related]
3. prex2 gene's expression in gastric antral epithelial cells of patients with H. pylori infection.
Hedayati MA; Ahmadi S; Servatyari K; Sheikhesmaeili F
Arq Gastroenterol; 2021; 58(3):353-358. PubMed ID: 34705970
[TBL] [Abstract] [Full Text] [Related]
4. A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics.
Wang H; Ding Y; Chen Y; Jiang J; Chen Y; Lu J; Kong M; Mo F; Huang Y; Zhao W; Fang P; Chen X; Teng X; Xu N; Lu Y; Yu X; Li Z; Zhang J; Wang H; Bao X; Zhou D; Chi Y; Zhou T; Zhou Z; Chen S; Teng L
Gastric Cancer; 2021 Nov; 24(6):1227-1241. PubMed ID: 34095982
[TBL] [Abstract] [Full Text] [Related]
5. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.
Jin Y; Chen DL; Wang F; Yang CP; Chen XX; You JQ; Huang JS; Shao Y; Zhu DQ; Ouyang YM; Luo HY; Wang ZQ; Wang FH; Li YH; Xu RH; Zhang DS
Mol Cancer; 2020 Oct; 19(1):154. PubMed ID: 33126883
[TBL] [Abstract] [Full Text] [Related]
6. Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for gastric cancer.
Zhou J; Zhao W; Wu J; Lu J; Ding Y; Wu S; Wang H; Ding D; Mo F; Zhou Z; Teng L; Chen S
Biomed Res Int; 2019; 2019():8103142. PubMed ID: 31312661
[TBL] [Abstract] [Full Text] [Related]
7. Clonal Structures of Regionally Synchronous gastric Adenomas and Carcinomas.
Jung SH; Kim SY; An CH; Lee SH; Jung ES; Park HC; Kim MS; Chung YJ; Lee SH
Clin Cancer Res; 2018 Oct; 24(19):4715-4725. PubMed ID: 29945994
[No Abstract] [Full Text] [Related]
8. MECP2 promotes the growth of gastric cancer cells by suppressing miR-338-mediated antiproliferative effect.
Tong D; Zhao L; He K; Sun H; Cai D; Ni L; Sun R; Chang S; Song T; Huang C
Oncotarget; 2016 Jun; 7(23):34845-59. PubMed ID: 27166996
[TBL] [Abstract] [Full Text] [Related]
9. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting p-rex2a.
Guo B; Liu L; Yao J; Ma R; Chang D; Li Z; Song T; Huang C
Mol Cancer Res; 2014 Mar; 12(3):313-21. PubMed ID: 24375644
[TBL] [Abstract] [Full Text] [Related]
